Results 71 to 80 of about 55,383 (212)

Inhibitors of the interferon response enhance virus replication in vitro.

open access: yes, 2014
This work was supported by the University of St Andrews (CSA, CES) and the Wellcome Trust (grant 087751/A/08/Z) (RER).Virus replication efficiency is influenced by two conflicting factors, kinetics of the cellular interferon (IFN) response and induction ...
Richard E. Randall   +8 more
core   +1 more source

Viral Detection and Clinical Disease Features in Pediatric Chronic Rhinosinusitis

open access: yesLaryngoscope Investigative Otolaryngology, Volume 11, Issue 3, June 2026.
ABSTRACT Objectives Chronic rhinosinusitis (CRS) results from complex host‐environment interactions with microbiome dysbiosis and viral infections postulated to drive inflammation and anatomic remodeling. This study investigates the impact of viral presence on pediatric sinonasal disease and clinical outcomes.
Mary C. Wilding   +7 more
wiley   +1 more source

An unbiased genetic screen reveals the polygenic nature of the influenza virus anti-interferon response

open access: yes, 2014
Influenza A viruses counteract the cellular innate immune response at several steps, including blocking RIG I-dependent activation of interferon (IFN) transcription, IFN-dependent upregulation of IFN-stimulated genes (ISGs) and the activity of various ...
Fernández, Yolanda   +23 more
core   +1 more source

Unraveling Oral Dysbiosis: Microbial Complexity in Common Oral Diseases

open access: yesMicrobiologyOpen, Volume 15, Issue 3, June 2026.
The oral microbiome undergoes dynamic establishment from birth, maturing into a resilient ecosystem. Perturbation of this homeostasis—driven by dietary, immunological, and anatomical factors—triggers dysbiosis, which underpins the pathogenesis of major oral diseases, including dental caries, periodontal disease, salivary gland disorders, oral mucosal ...
Zixi Kang   +8 more
wiley   +1 more source

Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3

open access: yesReviews in Medical Virology
ABSTRACT Human parainfluenza virus‐type 3 (HPIV3) is a respiratory virus responsible for mild illnesses in most of the population and severe illnesses, such as bronchiolitis and pneumonia, in young children, immunocompromised individuals and the elderly.
Clémence Vacher   +4 more
openaire   +2 more sources

Optineurin negatively regulates the induction of IFNβ in response to RNA virus infection [PDF]

open access: yes, 2010
The innate immune response provides a critical defense against microbial infections, including viruses. These are recognised by pattern recognition receptors including Toll-like receptors (TLRs) and RIG-I like helicases (RLHs).
Harris, M.   +42 more
core   +1 more source

The First Iranian Record of Suncus Murinus [PDF]

open access: yesActa Medica Iranica, 1969
199 human serum samples were examined for the presence of Myxovirus Parainfluenza 3 (MPI 3) haemagglutination inhibition (HI) antibodies. or tbe total male sera, 75% and female 70.52% had HI antibody titers of t:32 or greater.
A. farhang Azad
doaj   +2 more sources

Antimicrobial prescribing guidelines for feedlot cattle

open access: yes
Australian Veterinary Journal, EarlyView.
P Cusack   +4 more
wiley   +1 more source

Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants

open access: yesPediatric Pulmonology, Volume 61, Issue 6, June 2026.
ABSTRACT Introduction Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024.
Marine Tarizzo   +7 more
wiley   +1 more source

Inhibition of human parainfluenza virus type 3 infection by novel small molecules [PDF]

open access: yesAntiviral Research, 2008
Human parainfluenza virus type 3 (HPIV3) is an important respiratory tract pathogen of infants and children. There are no vaccines or antivirals currently approved for prevention or treatment of HPIV3 infection. Towards developing an antiviral therapy to combat HPIV3 infection, we have established a green fluorescent protein (GFP)-tagged HPIV3 infected-
Hongxia, Mao   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy